B. Diaz

Single-agent Foxo1 inhibition normalizes glycemia and induces gut β-like cells in streptozotocin-diabetic mice

This study shows that Foxo1 inhibitors reduce blood glucose and generate gut β-like cells in diabetic mice, suggesting they could be an alternative to insulin.

Triple Notch/Tgfβ/FoxO1 blockade converts multiple intestinal sub-lineages into β-like cells and lowers glycemia in diabetic animals